Industry M&A Weekly: Accelerant's $4B Take-Private, Stripe's Reported $7B OpenRouter Deal, and Four More

Six transactions met the issue's inclusion bar between August 12 and August 19, 2026 (UTC). The confirmed deals range from Thoma Bravo's more-than-$4 billion take-private of insurance marketplace Accelerant to three biotech asset transactions whose final prices depend on regulatory or commercial milestones. The largest reported deal is Stripe's potential purchase of OpenRouter for more than $7 billion; Stripe has not confirmed it. 123

The common question is what the buyer is paying to control. In fintech and SaaS, the answer is a distribution or access layer: an insurance marketplace, an options-based ETF franchise, or a gateway to many AI models. In biotech, buyers are purchasing programs close enough to a clinical or regulatory decision to price the next risk rather than fund discovery from scratch.

Thoma Bravo agreed to buy Accelerant for more than $4 billion in cash, or $20.25 per share. The price represented a 49% premium to Accelerant's previous closing price. The transaction is expected to close in the first half of 2027, subject to insurance regulatory approvals. A 6% annual ticking fee will accrue to shareholders if the closing is delayed by those approvals. 1

Accelerant was founded in 2018 by insurance-industry veterans. Its marketplace connects niche underwriters with institutional investors and uses data to make specialty-insurance placement faster and cheaper. The company went public in July 2025, but its shares had traded below the $21 IPO price. Altamont Capital Partners, its largest investor, and the founders plan to retain equity alongside Thoma Bravo. 1

Thoma Bravo said Accelerant had built something rare in specialty insurance. The buyer brings a software and data-investing history, including its ownership of insurance-technology company Nearmap, which bought claims-services firm itel for more than $1.3 billion in 2025. The stated rationale is to give Accelerant room to focus on the operating business away from public-market pressure while adding it to Thoma Bravo's insurance-technology portfolio. 1

The asset being bought is therefore the marketplace's underwriting network and data workflow, not simply a software license. The retained equity also keeps the founders and existing sponsor exposed to the next phase of that network's growth.

TechCrunch reported, citing Bloomberg, that Stripe had finalized a deal to buy OpenRouter for more than $7 billion. Stripe told TechCrunch that it does not comment on rumors or speculation, so the transaction belongs in the reported column rather than the confirmed column. 3

OpenRouter gives customers one access point to different AI models and helps them choose a model based on task and budget. The company said it had 8 million global users and access to more than 400 models. In May, it raised a $113 million Series B at a reported $1.3 billion valuation, with Sequoia, Andreessen Horowitz, Menlo Ventures, and Alphabet's CapitalG among its investors. 3

Stripe's rationale has not been stated publicly. If the reported price and closing are accurate, Stripe would be buying a neutral model-routing layer that reduces customer lock-in to one model provider. That would extend Stripe's role from payments infrastructure into a control point for the software and compute choices made inside AI products. The second sentence is an inference from OpenRouter's described product, not a disclosed Stripe commitment. 3

The valuation jump is the point to watch. A reported price above $7 billion would be more than five times OpenRouter's reported May valuation, but the public record still lacks confirmed consideration, closing mechanics, and integration plans.

Goldman Sachs will acquire NEOS Investments for as much as $2.25 billion. NEOS manages $30 billion across 19 exchange-traded funds, or ETFs, that use options to generate income and limit downside risk. The deal is expected to close in the first quarter of 2027. 2

Goldman said the acquisition would complement its capabilities in buffer, managed-outcome, and income strategies. Reuters reported that the bank's active-ETF assets would reach $80 billion after the deal, and that NEOS co-founders Troy Cates and Garrett Paolella would join Goldman as partners. NEOS's products use options to shape income and drawdown exposure, giving Goldman a packaged product set rather than a single fund to distribute. 2

Goldman's stated rationale is to expand active asset management as institutions seek recurring income and protection against portfolio drawdowns. The transaction also fits the bank's broader shift toward steadier asset- and wealth-management revenue: Reuters reported that the segment produced $4.6 billion in second-quarter net revenue, up 20% from a year earlier. 2

The headline value is capped rather than fixed at $2.25 billion. The economic bet is on the durability of options-based ETF demand and on Goldman's ability to place NEOS's products through a larger distribution and wealth-management platform.

Leo Pharma agreed to acquire rights to dersimelagon from Tanabe Pharma in a deal worth up to $435 million in upfront and near-term milestone payments. The contract also includes downstream milestones and tiered royalties on net sales. The companies did not disclose the split between the upfront payment and near-term milestones. 4

Dersimelagon is an experimental oral medicine for erythropoietic protoporphyria and X-linked protoporphyria, two rare genetic conditions that can cause severe reactions to sunlight, including pain, rashes, and swelling. Tanabe submitted the drug to the FDA in June. A Phase 3 study found that patients could spend more time in sunlight with fewer episodes of pain, and the FDA has granted Fast Track and Orphan Drug designations. 4

Leo said the rights acquisition would expand its rare-dermatology pipeline with a late-stage oral candidate. The deal extends the company's recent effort to add late-stage medicines, after its purchase of gene-therapy specialist Reply and its partnership with Boehringer Ingelheim around Spevigo. 4

This is a rights transaction, not a purchase of Tanabe or its employees. Leo is paying for a defined route to commercialization while leaving the final price tied to review, launch, and sales outcomes. The structure gives Leo access to a late-stage asset without buying the full Japanese pharmaceutical company.

BioMarin agreed to acquire privately held Alesta Therapeutics for $275 million up front and as much as $215 million in development and regulatory milestones. The deal is expected to close by the end of September and will be funded with BioMarin's cash. Before closing, Alesta will spin out a separate company with its employees to develop another undisclosed drug. 5

Alesta's lead candidate, ALE1, is in a Phase 1/2 trial for hypophosphatasia, a genetic disorder that interferes with bone mineralization and can cause fractures, tooth loss, and muscle weakness. The drug acts on a novel target that lowers inorganic pyrophosphate, a metabolite involved in the disease. 5

Alesta is based in the Netherlands. It closed a €65 million Series A in early 2025 led by Frazier Life Sciences and Droia Ventures, with Novartis's venture arm among the other participants. BioMarin said ALE1 could reach its largest addressable patient population and would join a muscle-and-bone portfolio that includes Voxzogo, BMN 333, and BMN 351. 5

BioMarin is buying a clinical program with a defined disease target and an active trial, while Alesta's other program remains outside the transaction through the planned spinout. The up-front payment buys control of the lead asset; the milestone package keeps part of the price tied to evidence that the program works and can reach patients.

PTC Therapeutics agreed to pay up to $211 million for Sangamo Therapeutics's ST-920, also known as isaralgagene civaparvovec. The package consists of $111 million in cash, $80 million if the gene therapy receives accelerated FDA approval, and another $20 million for full approval. PTC won the program in a competitive bankruptcy auction. 6

ST-920 is a one-time infusion designed to deliver a working copy of the GLA gene to patients with Fabry disease. The disease is caused by mutations that reduce a critical enzyme and allow fatty substances to build up inside cells. Sangamo had already started a rolling FDA submission, and PTC plans to finish the application in the fourth quarter with a potential 2027 launch. 6

Sangamo is a decades-old gene-medicine company that pioneered zinc-finger editing technology, but research setbacks and failed partnerships left it in Chapter 11. PTC said the program fits its rare-disease business; the buyer also avoids starting a confirmatory study because the regulatory application is already underway. 6

The structure puts a relatively small cash payment ahead of a much larger regulatory decision. PTC receives a near-term path to a potential product, while the seller's distressed process gives the buyer a way to pay more only if approval milestones arrive.

Accelerant connects specialty underwriters with institutional capital. NEOS packages options-based income and risk management into ETFs that Goldman can distribute. OpenRouter, if the reported Stripe transaction closes, would give Stripe a model-selection layer used across many AI systems. These are different products, but each target already sits between a customer and a fragmented supply base. 123

The strategic value is the position around the asset. A buyer can add capital, distribution, or infrastructure after the transaction, but rebuilding the trust, data, and relationships that make the access point useful would take longer than buying it.

All three biotech transactions separate control today from final payment. Leo's dersimelagon rights deal includes milestones and royalties; BioMarin pays Alesta $275 million before up to $215 million in development and regulatory payments; and PTC's ST-920 price rises from $111 million in cash to $211 million only if approval milestones are reached. 456

The arrangements match different stages of risk. Dersimelagon is already under FDA review, ALE1 is in Phase 1/2, and ST-920 has a rolling submission underway. Buyers gain control before the final verdict, while sellers receive more value if the clinical or regulatory case survives.

Accelerant's founders and largest investor retain equity after the take-private. Alesta will spin out its employees and another program before BioMarin closes. PTC bought only ST-920 through Sangamo's bankruptcy process, while Leo bought rights rather than the whole company. These structures keep the buyer focused on a chosen asset and leave other risks, people, or programs outside the transaction. 156

For deal readers, the headline price therefore says less than the control boundary. The useful comparison is what moves to the buyer at signing, what remains contingent, and which employees, distribution agreements, or other programs stay outside the perimeter.

This issue covers transaction disclosures and reported status changes from August 12 through August 19, 2026 (UTC). Six deals met the minimum count and had accessible evidence for value, structure, buyer rationale, and target or asset background. OpenRouter is the exception to confirmed status: TechCrunch attributed the more-than-$7 billion figure to Bloomberg, while Stripe said it does not comment on rumors or speculation. The biotech totals separate upfront consideration from milestones, royalties, and approval payments; they are maximum economics rather than cash paid at signing. No deal announced after the August 19 publication cutoff is included.